Please use this identifier to cite or link to this item:
10.1186/s13053-018-0092-2
Title: | Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer : A retrospective cohort analysis and literature review |
Authors: | Sæther, Nikolai Havn Skuja, Elina Irmejs, Arvids Maksimenko, Jelena Miklasevics, Edvins Purkalne, Gunta Gardovskis, Janis Rīga Stradiņš University |
Keywords: | BRCA1;Breast cancer;Cisplatin;Neoadjuvant;PCR;Platinum;3.2 Clinical medicine;1.1. Scientific article indexed in Web of Science and/or Scopus database;Oncology;Genetics(clinical);SDG 3 - Good Health and Well-being |
Issue Date: | 27-Apr-2018 |
Citation: | Sæther , N H , Skuja , E , Irmejs , A , Maksimenko , J , Miklasevics , E , Purkalne , G & Gardovskis , J 2018 , ' Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer : A retrospective cohort analysis and literature review ' , Hereditary cancer in clinical practice , vol. 16 , no. 1 , 9 . https://doi.org/10.1186/s13053-018-0092-2 |
Abstract: | Background: There is increasing evidence of high platinum sensitivity in BRCA-associated breast cancer. However, evidence from randomized trials is lacking. The aim of this study was to analyze the results of platinum-based chemotherapy for BRCA1-positive breast cancer in a neoadjuvant setting. Methods: A retrospective study was performed by obtaining information from patient files. The results were compared with the available data from a literature review. Results: Twelve female patients with BRCA1 gene mutations who had stage I to III breast cancers were eligible for evaluation. They received platinum-based neoadjuvant chemotherapy between 2011 and 2016. Eleven patients received a combination of cisplatin and doxorubicin, and one patient received carboplatin and docetaxel. All patients underwent mastectomy after chemotherapy. Ten patients (83%) achieved pathological complete remission (pCR). The observed pCR rate was comparable to existing results found in similar studies. Conclusion: The results of the study confirm the high pCR rate in BRCA1-positive breast cancer after platinum-based neoadjuvant chemotherapy. Larger randomized studies and longer follow-up times are necessary to evaluate the role of platinum-based therapies in BRCA1-positive breast cancer. |
Description: | Publisher Copyright: © 2018 The Author(s). |
DOI: | 10.1186/s13053-018-0092-2 |
ISSN: | 1731-2302 |
Appears in Collections: | Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure |
Files in This Item:
File | Size | Format | |
---|---|---|---|
Platinum_based_neoadjuvant_chemotherapy.pdf | 536.68 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.